The mitomycin bioreductive antitumor agents: Cross-linking and alkylation of DNA as the molecular basis of their activity

Pharmacology and Therapeutics

Volumn 76, Issue 1-3, 1997, Pages 73-87

  Tomasz, Maria ^a   Palom, Yolanda ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Bioreductive; DNA adducts; DNA cross linking; Mitomycin; Mitosene

Indexed keywords

4 FORMYL 6,9 DIHYDROXY 14 OXA 1,11 DIAZATETRACYCLO[7.4.1.0 2,7 0 10,12]TETRADECA 2,4,6 TRIEN 8 YLMETHYLCARBAMATE; 7 N [2 (4 NITROPHENYLDITHIO)ETHYL]MITOMYCIN C; 7 N [2 [[2 (GAMMA GLUTAMYLAMINO)ETHYL]DITHIO]ETHYL]MITOMYCIN C; DECARBAMOYLMITOMYCIN C; FR 66979; FR 673; MITOMYCIN; MITOMYCIN A; MITOMYCIN C; MITOMYCIN C DERIVATIVE; MITOMYCIN DERIVATIVE; PORFIROMYCIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CHO CELL; DNA ALKYLATION; DNA CROSS LINKING; DNA DAMAGE; DNA DRUG COMPLEX; DNA SEQUENCE; DRUG CONFORMATION; DRUG STRUCTURE; ENZYME ACTIVATION; HUMAN; NONHUMAN; PRIORITY JOURNAL;

EID: 0031278015     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(97)00088-0     Document Type: Review

References (112)

1. Armstrong, R. W., Salvati, M. E. and Nguyen, M. (1992) Novel interstrand cross-links induced by the antitumor antibiotic carzinophillin/azinomycin B. J. Am. Chem. Soc. 114: 3144-3145.
2. Arora, S. K., Cox, M. B. and Arjunan, P. (1990) Structural, conformational and theoretical binding studies of antitumor antibiotic porfiromycin, a covalent binder of DNA, by X-ray, NMR, and molecular mechanics. J. Med. Chem. 33: 3000-3008.
3. Basu, A. K., Hanrahan, C. J., Mahla, S. A., Kumar, S., Bizanek, R. and Tomasz, M. (1993) Effect of site-specifically located mitomycin C-DNA monoadducts on in vitro DNA synthesis by DNA polymerases. Biochemistry 32: 4708-4718.
4. Belcourt, M. F., Hodnick, W. F., Rockwell, S. and Sartorelli, A. C. (1996a) Bioactivation of mitomycin antibiotics by aerobic and hypoxic Chinese hamster ovary cells overexpressing DT-diaphorase. Biochem. Pharmacol. 51: 1669-1678.
5. Belcourt, M. F., Hodnick, W. F., Rockwell, S. and Sartorelli, A. C. (1996b) Differential toxicity of mitomycin C and porfiromycin to aerobic and hypoxic Chinese hamster ovary cells overexpressing human NADPH:cytochrome c (P-450) reductase. Proc. Natl. Acad. Sci. USA 93: 450-460.
6. Bird, A. P. (1980) DNA methylation and the frequency of CpG in animal DNA. Nucl. Acids Res. 8: 1499-1504.
7. Bizanek, R., McGuinness, B. F., Nakanishi, K. and Tomasz, M. (1992) Isolation and structure of an intrastrand cross-link adduct of mitomycin C and DNA. Biochemistry 31: 3084-3091.
8. Bizanek, R., Chowdary, D., Arai. H., Kasai, M., Hughes, C. S., Sartorelli, A. C., Rockwell, S. and Tomasz, M. (1993) Adducts of mitomycin C and DNA in EMT6 mouse mammary tumor cells: effects of hypoxia and dicumarol on adduct patterns. Cancer Res. 53: 5127-5134.
9. Bligh, H. F., Bartoszek, A., Robson, C. N., Hickson, I. D., Kasper, C. B., Begges, J. D. and Wolf, C. R. (1990) Activation of mitomycin C by NADPH:cytochrome P-450 reductase. Cancer Res. 50: 7789-7792.
10. Borowy-Borowski, H., Lipman, R., Chowdary, D. and Tomasz, M. (1990a) Duplex oligonucleotides cross-linked by mitomycin C at a single site: synthesis, properties and cross-link reversibility. Biochemistry 29: 2992-2999.
11. Borowy-Borowski, H., Lipman, R. and Tomasz, M. (1990b) Recognition between mitomycin C and specific DNA sequences for cross-link formation. Biochemistry 29: 2999-3004.
12. Brendel, M. and Ruhland, A. (1984) Relationships between functionality and genetic toxicology of selected DNA-damaging agents. Mutat. Res. 133: 51-85
13. Brown, J. M. (1993) SR 4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumors. Br. J. Cancer 67: 1163-1170.
14. Caron, R. M. and Hamilton, J. W (1995) Preferential effects of the chemotherapeutic DNA cross-linking agent mitomycin C on inducible gene expression in vivo. Environ. Mol. Mutagen. 25: 4-11.
15. Carrano, A. V., Thompson, L. H., Stretka, D. G., Minkler, J. L., Mazrimas, J. A. and Fong, S. (1979) DNA crosslinking, sister chromatid exchange and specific locus mutations. Mutat. Res. 63: 175-188.
16. Carter, S. K. and Crooke, S. T. (eds) Mitomycin C: Curent Status and New Developments. Academic Press, New York.
17. Choi, D., Yoo, B., Colsen, K. L. Martin, G. G. and Kohn, H. (1995) C(10) halogen 10-des(carbamoyloxy)porfiromycins: synthesis, chemistry, and biological activity. J. Org. Chem. 60: 3391-3396.
18. Cummings, J., Spanswick, V. J. and Smyth, J. F. (1995) Re-evaluation of the molecular pharmacology of mitomycin C. Eur. J. Cancer 31A: 1928-1933.
19. Dedon, P. C. and Goldberg, I. H. (1992) Free-radical mechanism involved in the formation of sequence-dependent bistranded DNA lesions by the antitumor antibiotics bleomycin, neocarzinostatin and calicheamicin. Chem. Res. Toxicol. 5: 311-322.
20. Denissenko, M. F., Chen, J. X., Tang, M.-S. and Pfeifer, G. P. (1997) Cytosine methylation determines hotspots of DNA damage in the human p53 gene. Proc. Natl. Acad. Sci. USA 94: 3893-3898.
21. Dorr, R. T., Bowden, G. T., Albers, D. S. and Liddil, J. D. (1985) Interactions of mitomycin C with mammalian DNA detected by alkaline elution. Cancer Res. 45: 3510-3516.
22. Fujiwara, Y., Tatsumi, M. and Sasaki, M. S. (1977) Cross-link repair in human cells and its possible defect in Fanconi's anemia cells. J. Mol. Biol. 113: 635-649.
23. Fukuyama, T. and Goto, S. (1989) Synthetic approaches toward FR-900482: I. Stereoselective synthesis of a pentacyclic model compound. Tetrahedron Lett. 30: 6491-6494.
24. Gargiulo, D., Musser, S. S., Yang, L., Fukuyama, T. and Tomasz, M. (1995) Alkylation and cross linking of DNA by the unnatural enantiomer of mitomycin C: mechanism of the DNA sequence specificity of mitomycins. J. Am. Chem. Soc. 117: 9388-9398.
25. Geiduschek, E. P. (1961) "Reversible" DNA. Proc. Natl Acad. Sci. USA 47: 950-955.
26. Haffty, B. G., Son, Y. H., Moini, M., Papac, R., Fischer, D. Rockwell, S., Sartorelli, A. C. and Fischer, J. J. (1994) Porfiromycin as an adjunct to radiation therapy in squamous cell carcinoma of the head and neck: results of a phase I clinical trial Radiat. Oncol. Invest. 1: 297-304.
27. Hata, T., Sano, Y., Sugawara, R., Matsumae, A., Kanamorei, K., Shima, T. and Hoshi, T. (1956) Mitomycin, a new antibiotic from Streptomyces: I. J. Antibiot. Ser. A 9: 141-146.
28. He, Q.-Y., Maruenda, H. and Tomasz, M. (1994) Novel bioreductive activation mechanism of mitomycin C derivatives hearing a disulfide substituent in their quinone. J. Am. Chem. Soc. 116: 9349-9350.
29. Hoban, P. R., Walton, M. I., Robson, C. N., Godden, J., Stratford, I. J., Workman, P., Harris, A. L. and Hickson, I. D. (1990) Decreased NADPH:cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions. Cancer Res. 50: 4692-4697.
30. Hopkins, P. B., Millard, J. T., Woo, J., Weidner, M. F., Kirchner, J. J., Sigurdsson, S. T. and Raucher, S. (1991) Sequence preferences of DNA interstrand crosslinking agents: importance of minimal DNA structural reorganization in the crosslinking reactions of mechlorethamine, cisplatin and mitomycin C. Tetrahedron 47: 2475-2489.
31. Huang, H., Pratum, T. K. and Hopkins, P. B. (1994a) Covalent structure of the DNA-DNA interstrand cross-link formed by reductively activated FR66979 in synthetic DNA duplexes. J. Am. Chem. Soc. 116: 2703-2709.
32. Huang, H., Rajski, S. R., Williams, R. M. and Hopkins, P. B. (1994b) FR66979 requires reductive activation to cross-link DNA efficiently. Tetrahedron Lett. 35: 9669-9672.
33. Ihnat, M., Lavrivriere, J. P., Warren, A. J., La Ronde, N., Blaxall, J. R., Pierre, K. M., Turpie, B. W. and Hamilton, J W. (1997) Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agents. Clin. Cancer Res. 3: 1339-1346.
34. Ishida, T., Nishio, K., Kurokawa, H., Arioka, H., Fukumoto, K., Fukuoka K., Nomoto, T., Yokote, H., Hasegawa, S. and Saijo, N. (1997) Circumvention of glutathione-mediated mitomycin C-resistance by a novel mitomycin C analogue, KW-2149. Int. J. Cancer 75: 865-870.
35. Iyer, V. N. and Szybalski, W. (1963) A molecular mechanism of mitomycin action: linking of complementary DNA strands. Proc. Natl. Acad. Sci. USA 50: 355-362.
36. Iyer, V. N. and Szybalski, W. (1964) Mitomycins and porfiromycin: chemical mechanisms of activation and cross-linking of DNA. Science 145: 55-58.
37. Johnson, D. A., August, P. R., Schackleton, C., Liu, H. and Sherman, D. H. (1997) Microbial resistance to mitomycins involves a redox relay mechanism. J. Am. Chem. Soc. 119: 2576-2577.
38. 5CpG dinucleotide sequence in DNA by mitomycin C for alkylation and cross-linking. Bioorg. Med. Chem. 3: 851-860.
39. Josse, J., Kaiser, A. P. and Kornberg, A. (1961) Enzymatic synthesis of deoxyribonucleic acid: VIII. Frequencies of nearest neighbor base sequences in deoxyribonucleic acid. J Biol. Chem. 236: 864-875.
40. Kaplan, D. J. and Tomasz, M. (1982) Altered physico-chemical properties of the DNA - mitomycin C complex: evidence for a conformational change in DNA. Biochemistry 21: 3006-3013.
41. Kasai, M. and Arai, H. (1995) Novel mitomycin derivatives. Exp. Opin. Ther. Parents 5: 757-770.
42. 32P-post labeling analysis. Mutat. Res 202: 85-91.
43. Kennedy, K. A., Rockwell, S. and Sartorelli, A. C. (1980a) Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells. Cancer Res. 40: 2356-2360.
44. Kennedy, K. A., Teicher, B. A., Rockwell, S. and Sartorelli, A. C. (1980b) The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem. Pharmacol. 29: 1-8.
45. Keyes, S. R., Loomis, R., DiGiovanna, M. P., Pritsos, C. A., Rockwell, S. and Sartorelli, A. C. (1991) Cytotoxicity and DNA cross-links produced by mitomycin analogs in aerobic and hypoxic EMT6 cells. Cancer Commun. 3: 351-356.
46. Kim, S. Y. and Rockwell, S. (1995) Cytotoxic potential of monoalkylation products between mitomycins and DNA: studies of decarbamoyl mitomycin C in wild type and repair-deficient cell lines. Oncol. Res. 7: 39-47.
47. Kohn, H. and Wang, S. (1996) Studies on the mechanism of activation of C(7) ethylenediamine substituted mitomycin: relevance to the proposed mode of action of BMY-25067 and KW-2149. Tetrahedron Lett. 37: 2337-2340.
48. Kohn, H., Li, V., Schiltz, P. and Tang, M. (1992) On the origins of the DNA sequence selectivity of mitomycin monoalkylation transformations. J. Am. Chem. Soc. 114: 9218-9220.
49. Kohn, K. W. (1979) DNA as a target in cancer chemotherapy: measurement of macromolecular DNA damage produced in mammalian cells by anticancer agents and carcinogens, Methods Cancer Res. 16: 291-345.
50. Kono, M., Saitoh, Y., Sadai, M., Sato, A., Shirahata, K., Morimoto, M. and Ashizawa, T. (1989) Synthesis and antitumor activity of a novel water soluble mitomycin analog: 7-[2-[[2-(γ-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C. Chem. Pharm. Bull. 37: 1128-1130.
51. Kumar, S., Lipman, R. and Tomasz, M. (1992) Recognition of specific DNA sequences by mitomycin C for alkylation. Biochemistry 31: 1399-1407.
52. Lee, J.-H., Naito, M. and Tsuruo, I. (1994) Nonenzymatic reductive activation of 7-N-[[2-[[2-(γ-L-glutamylamino)ethyl]dithio] ethyl]]mitomycin C by thiol molecules: a novel mitomycin C derivative effective on mitomycin C-resistant tumor cells. Cancer Res. 54: 2398-2403.
53. Li, V. and Kohn, H. (1991) Studies on the bonding specificity for mitomycin C-DNA monoalkylation processes. J. Am. Chem. Soc. 113: 275-283.
54. Li, V.-S., Choi, D., Wang, Z., Jimenez, L. S., Tang, M.-S. and Kohn, H. (1996) Role of the C-10 substituent in mitomycin C-1-DNA bonding. J. Am. Chem. Soc. 118: 2326-2331
55. Lindsay, S. and Bird, A. P. (1987) Use of restriction enzymes to detect potential gene sequences in mammalian DNA. Nature 327: 336-338.
56. Lown, J. W., Begleiter, A., Johson, D. and Morgan, A. R. (1976) Studies related to antitumor antibiotics: V. Reaction of mitomycin C with DNA examined by ethidium fluorescence assay. Can. J. Biochem. 54: 110-119.
57. Masuda, K., Makamura, T., Shimomura, K., Shibata, T., Terano, H. and Kohsaka, M. (1988) A new antitumor antibiotic, FR-900482: interstrand DNA-DNA cross-links in L1210 cells. J. Antibiot. 41: 1497-1499.
58. Matbur P., Xu, J. and Dedon, P. (1997) DNA methylation affects the damage produced by enediyne anticancer drugs. Proc. Am. Assoc. Cancer Res. 38: 228.
59. Matsumoto, A., Vos, J.-M. and Hanawalt, P. C. (1984) Repair analysis of mitomycin C-induced DNA cross-linking in ribosomal RNA genes in lymphoblastoid cells from Fanconi's anaemia patients. Mutat. Res. 217: 185-192.
60. McClure, K. F. and Danishefsky, S. J. (1991) Cycloaddition reactions of aromatic nitroso compounds with oxygenated dienes: an approach to the synthesis of the FR-900482 family of antibiotics. J. Org. Chem. 56: 850-853.
61. McGuinness, B. F., Lipman, R., Goldstein, J., Nakanishi, K. and Tomasz, M. (1991) Alkylation of DNA by mitomycin A. Biochemistry 30: 6444-6453.
62. Mikami, K., Naito, M., Tomida, A., Yamada, M., Sirakusa, T. and Tsuruo, T. (1996) DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines. Cancer Res. 56: 2823-2826.
63. Millard, J. T. and Beachy, T. M. (1993) Cytosine methylation enhances mitomycin C cross-linking. Biochemistry 32 12850-12856.
64. Millard, J. T., Weidner, M. F., Raucher, S. and Hopkins, P. B. (1990) Determination of the DNA crosslinking sequence specificity of reductively activated mitomicin C at single nucleotide resolution: deoxyguanosine residues at CpG are crosslinked preferentially. J. Am. Chem. Soc. 112: 3637-3641.
65. Moore, H. W. (1997) Bioactivation as a model for drug design: bioreductive alkylation. Science 197: 527-532.
66. Norman, D., Live, D., Sastry, M., Lipman, R., Hingerty, B. E., Tomasz, M., Broyde, S. and Patel, D. J. (1990) NMR and computational characterization of mitomycin cross-linked to adjacent deoxyguanosines in the minor groove of the d(T-A-C-G-T-A)·d(T-A-C-G-T-A) duplex. Biochemistry 29: 2861-2876.
67. Ohga, T., Koike, K., Ono, M., Makino, Y., Itagaki, Y., Tanimoto, M., Kuwano, M. and Kohno, K. (1996) Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res. 56: 4224-4228.
68. Otsuji, N. and Murayama, I. (1972) Deoxyribonucleic acid damage by monofunctional mitomycins and its repair in E. coli. J. Bacteriol. 109: 475-483.
69. Palom, Y., Suresh Kumar, G., Belcourt, M. F., Arai, H., Kasai, M., Sartorelli, A. C., Rockwell, S. and Tomasz, M. (1997) A guanine-N7 adduct of 2,7-diaminomitosene is a dominant DNA lesion in mitomycin C-treated EMT6 mouse mammary tumor cells. Proc. Am. Assoc. Cancer Res. 38: 228.
70. Pan, S. (1990) Porfiromycin disposition in oxygen modulated P388 cells. Cancer Chemother. Pharmacol. 27: 187-193.
71. Pan, S., Yu, F. and Hipsher, C. (1993) Enzymatic and pH modulation of mitomycin C-induced DNA damage in mitomycin C-resistant HCT 116 human colon cancer cells. Mol. Pharmacol. 43: 870-877.
72. Peterson, D. M. and Fisher, J. (1986) Auto-catalytic quinone methide formation from mitomycin C. Biochemistry 25: 4077-4084.
73. Peterson, D. M., Fisher, J., Beall, H. D. and Ross, D. (1995) Non-covalent binding of a mitomycin C metabolite, 2,7-diaminomitosene, to duplex DNA. Cancer Lett. 90: 133-138.
74. Prakash, A. S., Beall, H., Ross, D. and Gibson, N. W. (1993) Sequence-selective alkylation and cross-linking induced by mitomycin C upon activation by DT-diaphorase. Biochemistry 32: 5518-5525.
75. Pratt, W. B., Ruddon, R. W., Ensminger, W. D. and Maybaum, J. (1994) Covalent DNA-binding drugs. In: The Anticancer Drugs, 2nd edn., pp. 108-154. Oxford University Press, New York and Oxford.
76. Ramos, L. A., Lipman, R., Tomasz. M. and Basu, A. K. (1997) Effect of a site-specifically located mitomycin C adduct in Escherichia coli. Proc. Am. Assoc. Cancer Res. 38: 182.
77. 32P-analysis of DNA adducts in somatic and reproductive tissues of rats treated with the anticancer antibiotic, mitomycin C. Mutat. Res 179: 75-88.
78. 5CpG dinucleotides. Mol. Cell. Biol. 17: 416-426.
79. Remers, W. A., Rao, S. N., Wunz. T. P. and Kollman, P. (1988) (Conformations of complexes between mitomycins and decanucleotides: 3. Sequence specificity, binding at C-10, and mitomycin analogs. J. Med. Chem. 31: 1612-1620.
80. Rink, S. M., Lipman, R., Alley, S. C., Hopkins, P. B. and Tomasz, M. (1996) Bending of DNA by the mitomycin C-induced GpG intrastrand cross-link. Chem. Res. Toxicol. 9: 382-389.
81. Rockwell, S. (1997) Hypoxia-directed drugs: use with irradiation. In: Infusion Chemotherapy Radiation Interaction, Rosenthal, C. J. (ed.) Elsevier, New York, in press.
82. Rodighiero, G., Magno, S. M., Dell'Acqua, F. and Vedaldi, D. (1978) Studies on the mechanism of action of mitomycin C. Farmaco 33: 651-666.
83. Ross, D., Beall, H. D., Siegel. D.. Traver, R. D. and Gustafson, D. L. (1996) Enzymology of bioreductive drug activation. Br. J. Cancer (Suppl. 27) 74: S1-S8.
84. Sartorelli, A. C. (1988) Therapeutic attack on hypoxic cells of solid tumors: presidential address. Cancer Res. 48: 775-778.
85. Sastry, M., Fiala, R., Lipman, R., Tomasz, M. and Patel, D. J. (1995) Solution structure of the monoalkylated mitomycin C-DNA complex. J. Mol. Biol 247: 338-359.
86. Sato, K., Akaike, T., Suga, M., Ando, M. and Maeda, H. (1994) Generation of free radicals from neocarzinostatin mediated by NADPH/cytochrome P-450 reductase via activation of enediyne chromophore. Biochem. Biophys. Res. Commun. 205: 1716-1723.
87. Schiltz, P. and Kohn, H. (1993) Studies on the reactivity of reductively activated mitomycin C. J. Am. Chem. Soc. 115: 10510-10518.
88. Schwartz, G. K., Haimovitz-Friedman, A., Dhupar, S. K., Ehleiter, D., Maslak, P., Lai, L., Laganzo, F., Jr., Kelsen, D. P., Fuks, Z. and Albino, A. P. (1995) Potentiation of apoptosis by treatment with the protein kinase C-specific inhibitor safingol in mitomycin C-treated gastric cancer cells. J. Natl. Cancer Inst. 87: 1394-1399.
89. Semmelhack, M. F., Gallagher, J. and Cohen, D. (1990) Bioreductive activation as a trigger for toxic effects of dynenucin. Tetrahedron Lett. 31: 1521-1522.
90. Siegel, D., Beall, H. Senekowitsch, C., Kasai, M., Arai, H., Gibson, N. W. and Ross. D. (1992) Bioreductive activation of mitomycin C by DT-diaphorase. Biochemistry 31: 7879-7885.
91. Spain, R. C. (1993) The case for mitomycin in non-small cell lung cancer. Oncology 50 (Suppl. 1): 35-52.
92. Suresh Kumar, G., He, Q.-Y., Behr-Ventura, D. and Tomasz, M. (1995) Binding of 2,7-diaminomitosene to DNA: model for the precovalent recognition of DNA by activated mitomycin C. Biochemistry 34: 2662-2671.
93. Suresh Kumar, G., Musser, S. M., Cummings, J. and Tomasz, M. (1996) 2,7-Diaminomitosene. Monofunctional mitomycin derivative, alkylates DNA in the major groove: structure and base-sequence specificity of the DNA adduct and mechanism of the alkylation. J. Am. Chem. Soc. 118: 9209-9217.
94. Suresh Kumar, G., Lipman, R., Cummings, J. and Tomasz, M. (1997) Mitomycin C-DNA adducts generated by DT-diaphorase: revised mechanism of the enzymatic reductive activation of mitomycin C. Biochemistry, in press.
95. Szybalski, W. and Iyer, V. N. (1964) Cross-linking of DNA by enzymatically or chemically activated mitomycins and porfiromycins, bifunctionally "alkylating" antibiotics. Fed. Proc. 23: 946-957.
96. Taatjes, D. J., Gaudiano, G., Resing, K. and Koch, T. H. (1997) Redox pathway leading to alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin. J. Med. Chem. 40: 1276-1286.
97. Teng, S. P., Woodson, S. A. and Crothers, D. M. (1989) DNA sequence specificity of mitomycin crosslinking. Biochemistry 28: 3901-3907.
98. Tomasz, M. (1994) The mitomycins: natural cross-linkers of DNA. In: Molecular Aspects of Anticancer Drug-DNA Interactions, Vol. 2, pp. 312-349, Neidle, S. and Waring, M. (eds.) MacMillan, London, and CRC Press, Fort Lauderdale.
99. Tomasz, M. (1995) Mitomycin C: small, fast and deadly (but very selective). Chem. Biol. 2: 575-579.
100. Tomasz, M., Mercado, C. M., Olson, J. and Chatterjie, N. (1974) The mode of interaction of mitomycin C with DNA and polynucleotides in vitro. Biochemistry 13: 4878-4887.
101. Tomasz, M., Chowdary, D., Lipman, R., Shimotakahara, S. Veiro, D., Walker, V. and Verdine, G. L. (1986) Reaction of DNA with chemically or enzymatically activated mitomycin C: isolation and structure of the major covalent adduct. Proc. Natl. Acad. Sci. USA 83: 6702-6706.
102. Tomasz, M., Lipman, R., Chowdary, D., Pawlak, J., Verdine, G. L. and Nakanishi, K. (1987) Isolation and structure of a covalent cross-link adduct between mitomycin C and DNA. Science 235: 1204-1208.
103. 3H]-porfiromycin adducts of EMT6 mammary tumor cell DNA. Cancer Commun. 3: 213-223.
104. Uchida, I., Takase, S., Kayakiri, H., Kiyoto, S. and Hashimoto, M. (1987) Structure of FR-900482, a novel antitumor antibiotic from a Streptomyces. J. Am. Chem. Soc. 109: 4108-4109.
105. Verdine, G. L. (1986) Binding of mitomycin C to a dinucleotide phosphate and DNA. Ph.D. Thesis, Columbia University, New York.
106. Vyas, D.M., Chiang, Y., Benigni, D., Rose, W. C. and Bradner, W. T. (1985) Novel disulfide mitosanes as antitumor agents. In: Recent Advances in Chemotherapy, Anticancer Section, pp. 485-486, Tsigami, J. (ed.) University of Tokyo Press, Tokyo.
107. 2G interstrand cross-link in a model synthetic 23 base pair oligonucleotide DNA duplex. Chem. Res. Toxicol. 9: 1063-1071.
108. 32P-postlabeling: time course for formation and removal of adducts and biochemical modulation. Cancer Res.
109. Weissbach, A. and Lisio, A. (1965) Alkylation of nucleic acids by mitomycin C and porfiromycin. Biochemistry 4: 196-200.
110. Williams, R. M., Rajski, S. R. and Rollins, S. B. (1997) FR900482, a close cousin of mitomycin C that exploits mitosene-based DNA cross-linking. Chem. Biol. 4: 127-137.
111. Xia, H., Pinto, T., Hu, X., Benson, P. J., Zaren, H. A., Gupta, V. and Singh, S. V. (1996) Lack of a role of glutathione in cellular nonenzymatic activation of BMS-181174, a novel analogue of mitomycin C. Cancer Res. 56: 3495-3498.
112. Yao, K.-S., Godwin, A. K., Johnson, C. and O'Dwyer, P. J. (1996) Alternative splicing and differential expression of DT-diaphorase transcripts in human colon tumors and in peripheral mononuclear cells in response to mitomycin C treatment. Cancer Res. 56: 1731-1736.